Slingshot members are tracking this event:
Theravance Biopharma (TBPH) announces new development partner, Celgene (CELG), for its multivalent NS5A inhibitor TD-6450
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Oct 28, 2015
Don’t see a project related to the catalyst you care about?
Related Keywords Td-6450, Hepatitis C, Phase 2a, Phase 2 Clinical Trial, Co-develop, Partnership